Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma

BACKGROUND AND PURPOSE: Isotretinoin (13-cis-retinoic acid; 13-cRA) is a differentiation inducer used to treat minimal residual disease after myeloablative therapy for high-risk neuroblastoma. However, more than 40% of children develop recurrent disease during or after 13-cRA treatment. The plasma c...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Pharmacol
Hlavní autoři: Sonawane, Poonam, Cho, Hwang Eui, Tagde, Ashujit, Verlekar, Dattesh, Yu, Alice L, Reynolds, C Patrick, Kang, Min H
Médium: Artigo
Jazyk:Inglês
Vydáno: BlackWell Publishing Ltd 2014
Témata:
Research Papers
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4294043/
https://ncbi.nlm.nih.gov/pubmed/25039756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12846
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky